Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$691.36MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Behrenbruch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,152
- Beta
- 0.60
- Country
- AU
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.97
Financials
Revenue
$691.36M+354444.5%Net Income
$55.51MEBITDA
$17.30MFree Cash Flow
$5.90M+417919.2%EPS (diluted)
$0.16Shares Outstanding (diluted)
356.89M+823.0%Operating Expenses
$376.53MCash & Debt
$363.63MReturn of Capital
$0.00Revenue by Segment (annual)
$40.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.21B | $-10.69M | $-0.03 |
| 2024 | $783.21M | $49.92M | $0.15 |
| 2023 | $502.55M | $5.21M | $0.02 |
| 2022 | $160.10M | $-104.08M | $-0.34 |
| 2021 | $7.60M | $-80.51M | $-0.29 |
| 2020 | $5.21M | $-44.89M | $-0.17 |
| 2019 | $3.48M | $-27.87M | $-0.12 |
| 2018 | $195.1K | $-13.83M | $-0.07 |
| 2017 | $0.00 | $-6.38M | $-0.05 |
| 2016 | $0.00 | $-44.0K | $-0.00 |
| 2015 | $0.00 | $-132.0K | $-0.00 |
| 2000 | $0.00 | $-497.0K | $-0.01 |
| 1999 | $0.00 | $-289.0K | $-0.01 |
Valuation
TLXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-50.00%Social Signal Score
Mentions (11)
- Newszacks.com·5d ago·Positive
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement Telix Pharmaceuticals is maintained at a “Buy” rating, supported by FDA approval of PIXCLARA and robust pipeline progress in oncology diagnostics and therapeutics. The company achieved the first FDA-approved FET-PET imaging agent for glioma, with potential label expansion into brain metastases via a phase 3 study. Phase 3 programs for TLX250-Tx in ccRCC and TLX591-Tx in mCRPC are advancing, with FDA alignment …
View source ↗ - Newsglobenewswire.com·22d ago·Negative
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
View source ↗ - Newsglobenewswire.com·34d ago·Negative
…in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for prostate cancer imaging in the …
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Telix Appoints David Gill as Chair MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately.
View source ↗ - Newsseekingalpha.com·42d ago·Neutral
…trongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain tumor imaging) and resubmission plans for TLX250-Px (kidney cancer imaging). TLX's radiopharmaceutical pipeline advances with pivotal studies in prostate cancer diagnostics and therapeutics, supported by robust financials and a recent $600 million convertible bond raise.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·47d ago·Neutral
Telix Pharmaceuticals H1 Earnings Call Highlights Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $38 million.
View source ↗ - Newsglobenewswire.com·47d ago·Positive
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.
View source ↗
Earnings
Fri, Feb 19(in 5 months)
Consensus estimate $-0.07 per share
Typical surprise -28.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$0.11 vs $0.04beat
- Thu, Feb 19$-0.01 vs $0.03miss
- Wed, Aug 20$-0.01 vs $0.13miss
- Thu, Feb 20$0.11 vs $0.09beat
- Thu, Aug 22$0.06 vs $0.09miss
- Thu, Feb 22$0.04 vs $0.05miss
Estimates and results for TLX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLX officers and directors.
- Bought
- $1.0m
- Sold
- —
3 trades
0 trades
- Smith Darren Charltonbought
- Behrenbruch Christianbought
- Behrenbruch Christianbought
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.